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Objectives: Counterfeit and substandard medicines pose a great threat to public health and 
the economy worldwide. Reports suggest their prevalence is increasing and can no longer be 
ignored. A detailed account on the current nature of the problem and identification of knowledge 
limitations in terms of geographical location, medicine classes, and type of medicine analysis 
performed is not available. Our objective was to systematically review articles that have reported 
investigations of counterfeit and substandard medicines.
Design: Systematic review.
Data sources: PubMed, Scopus, and ISI Web of Knowledge.
Data Selection: Prospective field quality surveys on counterfeit and substandard medicines 
were selected from all available records within the selected databases up to December 31, 
2013. All prospective studies performing chemical analysis on medicine samples were identi-
fied using the key search terms “counterfeit” or “substandard” and “medicine” or “drug” or 
“pharmaceutical.” The title, abstract, and/or full articles were reviewed for relevance according 
to a predetermined set of inclusion and exclusion criteria. Medicines procured from the Internet 
are beyond the scope of this review.
Results: Sixty-six research articles were found that fulfilled our inclusion criteria. The majority 
of medicine quality surveys were conducted in specific areas of Africa and Asia. Within these 
two continents, medicine quality reports covering the Northern part of Africa and the Western 
part of Asia in the Middle East are extremely scarce. Other continents such as North or South 
America and Europe were covered in limited articles, whereas the Australian continent had 
no reports. Moreover, most studies examined medicines that treat infectious diseases; very 
few articles addressed popular medicines for chronic diseases or clinically significant narrow 
therapeutic index medicines or cancer treatments, despite media reports of quality problems in 
these medicines. Furthermore, only six (9%) research articles attempted all levels of medicine 
quality analysis available through laboratory analysis, authentication of source, and package 
inspection to comprehensively identify the nature of the problem and so conclude whether the 
medicines were counterfeit or substandard.
Conclusion: Substandard and counterfeit medicines should be considered and identified 
through means of chemical analysis, physical analysis, authentication of source, and package 
inspection in any field medicine quality survey. More research is encouraged to examine the 
medicine quality in neglected parts of the globe and on neglected, yet popular and clinically 
significant, noncommunicable disease medicines.
Keywords: counterfeit, substandard, poor quality, SSFFC, medicine and drug
Introduction
Medicine safety, efficacy, and quality are the most important criteria in ensuring optimal 
treatment from medicines and are currently receiving increased attention in an era of 
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globalization and generic manufacturing.1,2 Medicines with 
questionable quality could either be counterfeit or substan-
dard, according to the World Health Organization (WHO). 
A counterfeit medicine is defined by the WHO as “one which 
is deliberately and fraudulently mislabeled with respect to 
identity and/or source.” Counterfeiting could include both 
branded and generic products and may include products 
with the correct ingredients or with the wrong ingredients, 
without active ingredients, with insufficient active ingredi-
ent, or with fake packaging.3 Substandard medicines, also 
referred to as out-of-specification products, are defined by the 
WHO as “products that do not meet the required specifica-
tion in terms of content and ingredients.”4,5 They are legally 
manufactured but do not conform to specifications as a result 
of inadequate manufacturing or poor storage conditions.6–9 
Recently, the term substandard/spurious/falsely labeled/falsi-
fied/counterfeit medicines (SSFFC) was used by the WHO 
to simultaneously describe both counterfeit and substandard 
medicines.10 This joint definition highlights the importance 
of identifying both counterfeit and substandard medicines in 
any proposed medicine quality survey.
The distinction between counterfeit and substandard 
medicines is imperative when applying appropriate strate-
gies to combat potential threats of either quality problem.11,12 
However, some dismiss this notion and argue that both 
counterfeit and substandard medicines are similar because 
they both claim to be something that in reality they are not.13 
Nevertheless, correctly identifying the type of medicine 
quality problem could aid governments and responsible 
bodies in determining the need to involve local or interna-
tional law enforcement, particularly when scarce economic 
resources are present. Counterfeit medicines are strongly 
linked with organized crime and would most likely require 
criminal experts to aid health care professionals to combat 
this problem, as demonstrated by the establishment of 
the International Medical Products Anti-Counterfeiting 
 Taskforce to support the WHO efforts to combat counterfeit 
medicines globally.14
Medicine quality problems could be fatal in extreme 
clinical outcomes and have also been associated with severe 
economic consequences. More than 700,000 deaths from 
tuberculosis and malaria have been strongly linked with inef-
fective counterfeit and substandard medicines worldwide.15,16 
Mortality has also been reported after heparin contamination 
in the United States and sexual enhancement drugs adulterated 
with large contents of hypoglycemic drugs in Singapore.17–20 
Moreover, substandard and counterfeit medicines have been 
related to morbidity, drug resistance, therapeutic failure, and 
toxicity.8,13,15,16 Economically, substandard and counterfeit 
medicines have been suggested to cause macroeconomic 
burdens worldwide by wasting limited resources, causing loss 
of productivity, and limiting investment of major pharmaceu-
tical companies into medicine research and development.7,8,21 
Furthermore, consequences of substandard and counterfeit 
medicines could result in loss of confidence in health care 
professionals and/or services.8,13,15,16
The WHO estimates that around 10% of all global phar-
maceutical supply is counterfeit and substandard, reaching 
up to 50% of the supply in developing countries and as low 
as 1% in the developed world.6,15,22 Moreover, it has been sug-
gested that the majority of reported SSFFC medicines were 
substandard, rather than counterfeit, yet they receive far less 
attention within the media and the scientific community.23,24 
Determining the exact prevalence rates of either counterfeit or 
substandard medicines could be a complex task and requires 
high-quality country-based medicine surveys, which are 
limited within the available literature.
The aim of this systematic review is to broadly explore the 
evidence of substandard and counterfeit medicines in scientific 
reports to identify current knowledge limitations and provide 
an overview report of the current situation. Previously, some 
reviews have focused on specific medicine categories or 
problems.13,23,25,26 Only one review comprehensively searched 
for substandard and counterfeit medicine articles covering the 
period from 1966 to 2006 without specifying a therapeutic 
medicine category.27 Recently, the first systematic review on 
the subject of counterfeit and substandard medicines was pub-
lished.28 However, Almuzaini et al have only reviewed some 
articles from a single therapeutic class that demonstrated high-
quality reporting, which could be useful in the determination 
of SSFFC prevalence rates but may not be comprehensive 
enough to describe the broad scope and nature of SSFFC 
medicines available in other reports. Further, the previous sys-
tematic review did not discuss the types of analysis performed 
in the included studies, nor did it identify therapeutic classes 
or global regions in which the quality of medicines remains 
largely unknown. This review attempts to cover these issues 
broadly to encourage future researchers on medicine quality 
to focus their attention on neglected medicines and neglected 
parts of the globe. Furthermore, this review discusses types of 
analysis currently performed in medicine quality surveys to 
identify areas of concern and to promote the consideration of 
counterfeit as well as substandard medicines when conducting 
any medicine quality survey.
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Methods
Searching the literature
Scopus, PubMed, and ISI Web of Knowledge databases have 
been searched for relevant research articles. The search cov-
ered the period from 1997, the year the first relevant citation 
was found, up to December 31, 2013. There was no language 
restriction applied on our search results.
The following key search terms were used in conjunction, 
using (AND) to identify related articles: substandard(s) or 
counterfeit(s); medicine(s) or drug(s) or pharmaceutical(s). 
The choice of key search terms was based on key search terms 
used in five previous literature reviews.13,23,25–27 The main dis-
tinction of our present review compared with most previously 
published reviews is its systematic nature and broader scope, 
as no medicine groups or settings were specifically chosen 
in the search terms and inclusion criteria used.
The definitions and criteria used to describe counterfeit 
and substandard medicines in this review are based on the 
widely accepted WHO definitions of each phenomenon, as 
cited earlier.3–5 On the basis of the WHO criteria, a counterfeit 
medicine could be determined by chemical analysis meth-
ods if medicine samples contained no, or the wrong, active 
ingredient. A counterfeit medicine could also be identified 
via medicine package analysis by visual comparison to a 
known genuine package. Other means of detecting coun-
terfeit medicines include authenticating its source through 
official consignment documents or communication with 
the stated manufacturer and regulatory organizations. In 
addition, deliberately manufactured substandard medicines 
are considered counterfeit, although this would be difficult 
to demonstrate without legal and criminal investigation 
by authorities. In contrast, a substandard medicine should 
always contain the correct active pharmaceutical ingredient 
(API), be produced from a legitimate source, and be without 
packaging defaults. Substandard medicines are present when 
the amount of API is outside the acceptable pharmacopeial 
limits, the sample does not meet other standards set by the 
pharmacopoeias, or medicines are past their expiry dates. 
Collectively, we refer to both counterfeit and substandard 
medicines as SSFFC medicines, in accordance with the latest 
WHO joint definition.10
Inclusion and exclusion criteria  
for articles in this review
Studies included in this review were original research articles 
that reported prospective medicine sample collection from 
their natural settings; these medicines were presumed to be 
readily available to patients. Further, all included articles 
must have reported conducting chemical tests for the identi-
fication and/or quantification of the API. Without performing 
chemical analysis, it would not be possible to determine 
whether a medicine sample was counterfeit or not, as no 
information on the API would be present. In addition, rel-
evant studies would include medicine samples from a wide 
range of different therapeutic categories and dosage forms 
without any restrictions.
In contrast, the exclusion criteria of articles would 
include studies that did not report primary collection of 
medicine samples or medicines procured from the Internet 
or  retrospectively collected through authority or innovator 
company seizures. Furthermore, studies that reported only 
physical or packaging testing without chemical analysis were 
excluded. Duplicate results and nonrelevant articles were also 
identified and excluded from this review.
Data presentation of articles  
in this review
This systematic review has been performed in accordance 
with Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses guidelines for systematic reviews.29 All 
percentages of SSFFC medicines available in this review are 
reported as cited from their primary source. Therefore, cau-
tion is advised, as methodological differences exist between 
articles. The data presented here do not allow for any estima-
tion of the SSFFC prevalence rate worldwide.
Results
Data extraction
The use of the selected search terms resulted in a total of 
3,861 hits from all databases. An initial screening of titles/
abstracts followed this, excluding nonrelevant and duplicate 
results to reduce the number of results to 1,288 research 
articles. Subsequently, a full review of articles was per-
formed that further excluded articles without primary data 
collection, such as reviews and opinions, articles containing 
retrospective sample collection of medicines (either donated 
or seized by authorities), medicines acquired through the 
Internet, nonrelated articles, studies without medicine sample 
collection, and studies that did not perform chemical analysis 
of samples. This strategy reduced the final number of the 
included articles to 66. A flowchart illustrating the method 
used for article selection in this review and different exclu-
sion categories is shown in Figure 1.
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Location of included studies
The majority of reported studies prospectively examining 
SSFFC medicines were conducted in the African continent 
(31/66; 47%). Nigeria and Ghana alone were selected for 
more than 50% (17/31) of the studies in Africa. In Asia, 23/66 
(35%) of the SSFFC medicine quality surveys were conducted, 
mostly in the South Eastern part of Asia (Tables 1–4). Eight 
research articles were performed in the southern parts of the 
continent in Pakistan, Bangladesh, and India.30,32,37,54,61,72,76,78 
Overall, only two studies (3%) were published that addressed 
SSFFC medicines in the western part of Asia, also known 
to be part of the Middle East.82,87 Elsewhere, 6/66 (9%) of 
studies were conducted in more than one continent simultan-
eously.30,32,53,71,79,92 Moreover, three studies were performed in 
North/South America (4%),65,67,68 and two in Eastern Europe 
(3%).83,84 Only one study was located in the borderline area 
between Asia and Australia in Papua New Guinea.33
Medicine therapeutic classes  
in included studies
Substandard and counterfeit medicines were found from 
various therapeutic categories. However, most SSFFC stud-
ies 57/66 (86%) were focused on medicines that treat infec-
tious diseases. Antimalarial, antibiotic, and antituberculosis 
 medicines were examined in 30/66 (46%), 10/66 (15%), and 
5/66 (8%) of the located studies, respectively (Tables 1, 2, 
and 4). The combination of more than one class of medicines 
to treat infectious diseases was found in 12/66 (18%) of the 
articles.32,33,37,39,42,47,51,53,71,72,79,89 Other infectious diseases such 
as leishmaniasis medicines were investigated on one (2%) 
other occasion.54 In contrast, medicines for treatment of non-
communicable diseases were present in only 9/66 (14%) of 
the cited literature.31,32,47,58–60,67,77,80 The analgesic paracetamol 
was investigated on two separate occasions.32,58 Similarly, 
antihypertensive medications were surveyed in only two 
studies.59,77 Nonsteroidal anti-inflammatory agent aspirin was 
analyzed in one further study.47 The antihistamine medicine 
chlorpheniramine was only present in one survey.60 Narrow-
therapeutic index medicines also were the focus of only one 
published study.67 Other types of medicines such as ergome-
trine, oxytocin, and erythropoietin appeared in only one study 
each.31,80 A single study attempted to collect samples from 
various therapeutic categories simultaneously.32
evidence and nature of SSFFC medicines
Overall, substandard medicines were found in the major-
ity of prospective SSFFC medicine studies (60/66; 91%) 
(Tables 1 and 4). Counterfeit medicines were less evident in 
Key search terms:
Substandard(s) or counterfeit(s) AND
medicine(s) or drug(s) or pharmaceutical(s) 
Potentially relevant
articles (n=1,288)  
Studies included (n=66)  
All identified hits
(n=3,861)  
PubMed database: 890 hits
Scopus database: 1,607 hits
ISI Web of Knowledge database: 1,364 hits
•   Review title, abstract and keywords
•   Exclude duplicates (n=1,439) 
•   Exclude non-relevant titles (n=1,134)  
•   Full review of articles
•   Exclude opinion, letters, debates etc, (n=663) 
•   Exclude reviews (n=159) 
•   Exclude Internet source (n=27) 
•   Exclude perception articles (n=23) 
•   Exclude retrospective collection or method
    development articles (n=236)  
•   Exclude articles on package security or track and
     trace technology (n=49) 
•   Exclude articles with no medicine collection or no
     laboratory analysis (n=46)  
•   Exclude further non-related articles (n=22) 
•   Add articles from bibliography (n=3) 
Figure 1 Flow chart for articles inclusion in systematic review.
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29/66 (44%) of available studies (Tables 1 and 2).  Counterfeit 
and substandard medicines were simultaneously found 
in 24/66 (36%) articles (Table 1). Few studies 5/66 (8%) 
reported only evidence of counterfeiting in the medicine 
samples collected (Table 2). Evidence of medicines being 
only substandard, rather than counterfeit, was found in 
36/66 (55%) of the articles (Table 4). One study did not find 
evidence of counterfeit or substandard medicines in their 
sample (Table 3).
Several types of SSFFC problems have been reported in 
the selected literature. It was noted that more than one medi-
cine quality problem typically exists within each prospec-
tive medicine quality survey (Tables 1, 2, and 4). The most 
reported medicine quality problem was failure to comply with 
the specified API limits in 46/66 (70%) of cases (Tables 1 
and 4). Failure of dissolution or disintegration tests has been 
reported in 24/66 (36%) of the articles (Tables 1 and 4). The 
presence of either no API12,31–33,36,37,40,42,44,45,47–49,51–56 or the 
wrong API12,38,50,55 was reported in 20/66 (30%) and 4/66 
(6%) cases, respectively. Other problems were also reported, 
including fake package,36,57 fake hologram,12,56,57 manufacturer 
does not exist,12,33,46 manufacturer confirmed a nonauthentic 
batch,35,56 expired medicines,31,50,68 no origin country stated,51 
no manufacturer address,33,34,43 no manufacturer stated,44 no 
expiry date,34,41,50 unusual interval between manufacturing and 
expiry date,55 wrong name on package or leaflet,12 wrong spell-
ing of “tablet,”55,56 use of a different font,56 different medici-
nal taste,57 heavier weight,57 nonauthorized manufacturer,86 
absence of trade name,44 signs of deterioration,53 and diverted 
medicines45,80 intended for distribution in one location and 
found to be on sale in another market.
Type of analysis identified  
in the included studies
Four distinctive types of analysis can be used to distinguish 
between a genuine and SSFFC medicines; namely, authenti-
cation of the supplier, visual package inspection, and chemi-
cal and physical analysis (Tables 1–4). Authentication of the 
medicine source via contact with manufacturer, health regu-
latory agencies, or Internet search has been only attempted 
in 10/66 (15%) of the selected studies.12,33,35,40,46,56,62,80,86,88 
Package inspection was more popular than authentication, 
being reported in 39/66 (59%) of studies, with the majority 
reporting obvious spelling errors and basic label information 
(medicine name, dosage, manufacturer, expiry date, and lot 
number), as shown in Tables 1, 2, and 4. As for the chemical 
analysis, high-performance liquid chromatography and thin-
layer chromatography (TLC) were most widely used in 40/66 
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(61%) and 19/66 (29%) of studies, respectively (Tables 1, 
2, and 4). Other chemical analysis methods were reported 
such as color reaction tests,39,40,43,48,49,52,54–57,66 spectroscopic 
techniques,12,43,54–56,58,61,63,69,71,72,75,79,92 and titration,47,50,52,59,63,73 
but remain less frequently used. Moreover, physical analysis 
tests were performed in 39/66 (59%) of the studies (Tables 1, 
2 and 4). The most common physical tests reported were 
disintegration and/or dissolution tests in 36/39 (92%) cases 
(Tables 1, 2, and 4). Other less frequently used physical 
analysis tests include content uniformity,33,42,43,45,66 weight 
measurement,33,35,42,47,52,57,60,63,65,67,73 hardness,32,65,73 and 
friability32,43,60,65,73 tests. Interestingly, only six studies (9%) 
reported all four types of analysis in an attempt to clearly 
identify and classify the type of SSFFC problem, where 
present, in any medicine sample.33,35,40,62,86,88
Discussion
Neglected parts of the world  
in SSFFC surveys
According to our findings, the vast majority of prospective 
medicine quality studies were conducted in small parts of 
Africa and Asia. These efforts can be attributed to an attempt 
to counteract nonexistent or lower levels of regulation in 
these pharmaceutical markets.94 However, some parts of 
these two continents still have limited scientific research 
addressing the problem of SSFFC medicines, mainly in the 
Middle East and North Africa. In Yemen, 32% of selected 
antimalarial medicines failed analysis tests, and the major-
ity of these were substandard, having lower than accepted 
API% limits and unacceptable dissolution rates.87 Another 
study explored the API content of the antibiotic amoxicillin 
purchased from Egypt, Lebanon, Jordan, and Saudi Arabia 
and found that more than 50% of samples had lower API% 
than accepted by pharmacopeial limits, and therefore were 
considered substandard.82 A multicountry medicine quality 
survey found that 12% of samples collected from Egypt 
failed at least one medicine quality test and can be considered 
substandard.71 None of these studies reported an attempt 
to verify the source or analyze packages of the selected 
medicine samples to explore the possibility of counterfeit-
ing  activity. This may cause some concern, particularly with 
recent seizures of SSFFC medicines in this area. In addition, 
the currently unsettled political situation may be a catalyst 
for the increased prevalence of SSFFC medicines, as it allows 
them to escape immediate governmental attention.95 Reports 
of recent seizures of SSFFC medicines in this area can be 
mostly found in the media, which remains the main source 
of information regarding SSFFC medicines in this region 
with limited published scientific reports.95 Moreover, a WHO 
report on questionnaire responses from a number of health 
organizations in the Eastern Mediterranean Regional Office 
regarding counterfeit medicines has confirmed counterfeit 
seizures in this region by some respondent countries.96 In 
addition, this area could be of specific importance in terms 
of geographical location, as it separates two well-established 
regions of SSFFC medicine prevalence, according to our 
data, and is en route between potential counterfeit manu-
facturers in Asia56 and their global targeted markets. It is 
therefore suggested that several pilot studies be conducted 
to survey the quality of medicines in the Middle East and 
North Africa to assess the current medicine quality situation 
before any countermeasures or large-scale medicine quality 
surveys can be recommended. Elsewhere, such pilot studies 
have been shown to be instrumental in the assessment of 
the medicine quality situation in different countries and to 
have justified the need for further medicine quality surveys, 
where appropriate.30,37,57,78
Evidence from South America suggests that SSFFC med-
icines are available, but with only limited scientific research. 
A study found 11% of antimalarials to be substandard in 
seven South American countries using basic TLC chemi-
cal  analysis.68 The TLC analysis technique is limited by its 
inability to detect higher than 80% of API concentration in 
medicine samples41 which has been evident to exist in pre-
vious studies.31,41,44,46,50,52,53,61,63,66,70,73,76–78,87,91,93 It is therefore 
possible that the prevalence of SSFFC medicines in South 
America could be higher than the reported figures if more 
sophisticated chemical techniques for the quantification of 
API% content were used, such as high-performance liquid 
chromatography. Another study reported problems with low 
API% on a range of medicines procured from Mexico; of 
particular importance are some narrow therapeutic index 
Table 3 Study with no report of substandard or counterfeit medicines
Reference Country Medicine Sample  
size
Authenticate  
source
Visual  
analysis
Chemical  
analysis
Physical  
analysis
Results
Said et al58 Malaysia Paracetamol 16 NR NR Near-infrared 
spectroscopy
NR All samples passed but 
with variable quality
Abbreviation: NR, not reported.
Integrated Pharmacy Research and Practice 2014:3submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
80
Alghannam et al
T
ab
le
 4
 R
es
ea
rc
h 
ar
tic
le
s 
re
po
rt
in
g 
on
ly
 s
ub
st
an
da
rd
 m
ed
ic
in
es
R
ef
er
en
ce
C
ou
nt
ry
M
ed
ic
in
e
Sa
m
pl
e 
 
si
ze
A
ut
he
nt
ic
at
e 
 
so
ur
ce
V
is
ua
l a
na
ly
si
s
C
he
m
ic
al
  
an
al
ys
is
P
hy
si
ca
l a
na
ly
si
s
R
es
ul
ts
T
yp
e 
of
 s
ub
st
an
da
rd
/s
pu
ri
ou
s/
fa
ls
el
y 
la
b
el
ed
/f
al
si
fi
ed
/
co
un
te
rf
ei
t 
m
ed
ic
in
e 
pr
ob
le
m
H
ar
un
a 
et
 a
l59
N
ig
er
ia
A
nt
ih
yp
er
te
ns
iv
e 
 
m
et
hy
ld
op
a
4
N
R
N
R
N
on
aq
ue
ou
s 
 
tit
ra
tio
n
N
R
1/
4 
(2
5%
) 
 
su
bs
ta
nd
ar
d
Lo
w
 A
PI
%
A
ud
u 
et
 a
l60
C
on
go
A
nt
ih
is
ta
m
in
e 
 
ch
lo
rp
he
ni
ra
m
in
e
10
N
R
N
R
H
PL
C
 a
nd
 U
v
T
ab
le
t 
sh
ap
e,
  
si
ze
, t
hi
ck
ne
ss
,  
an
d 
w
ei
gh
t; 
 
di
si
nt
eg
ra
tio
n 
 
an
d 
fr
ia
bi
lit
y 
te
st
s
3/
10
 (
30
%
) 
 
su
bs
ta
nd
ar
d
Lo
w
 A
PI
%
R
am
ac
ha
nd
ra
n 
 
et
 a
l61
In
di
a
A
nt
i-T
B
1,
94
8 
 
ta
bl
et
s
N
R
N
R
Sp
ec
tr
om
et
ry
N
R
16
8/
1,
94
8 
(9
%
) 
 
su
bs
ta
nd
ar
d
Lo
w
 a
nd
 h
ig
h 
A
PI
%
K
ha
n 
et
 a
l62
C
am
bo
di
a
A
nt
ib
io
tic
  
am
ox
ic
ill
in
- 
cl
av
ul
an
ic
 a
ci
d
59
C
on
ta
ct
 w
ith
  
m
an
uf
ac
tu
re
r 
 
an
d 
lo
ca
l  
au
th
or
iti
es
Ba
si
c 
vi
su
al
  
an
al
ys
is
 o
f p
ri
m
ar
y 
 
an
d 
se
co
nd
ar
y 
 
pa
ck
ag
in
g
H
PL
C
St
ab
ili
ty
 a
nd
  
di
ss
ol
ut
io
n
12
/5
9 
(2
0%
) 
 
su
bs
ta
nd
ar
d
Lo
w
 A
PI
%
, f
ai
lu
re
 o
f c
on
te
nt
 
un
ifo
rm
ity
 a
nd
 d
is
so
lu
tio
n 
te
st
s
A
ffu
m
 e
t 
al
63
G
ha
na
A
nt
im
al
ar
ia
l  
ar
te
su
na
te
 a
nd
  
am
od
ia
qu
in
e
32
  
bl
is
te
rs
N
R
Ba
si
c 
vi
su
al
 a
na
ly
si
s 
 
an
d 
co
m
pa
re
d 
 
to
 g
en
ui
ne
T
itr
im
et
ri
c,
  
H
PL
C
, a
nd
  
sp
ec
tr
om
et
ry
T
ab
le
t 
w
ei
gh
t
14
/3
2 
(4
3.
75
%
) 
 
su
bs
ta
nd
ar
d
Lo
w
 a
nd
 h
ig
h 
A
PI
%
 m
os
tly
 
ar
te
su
na
te
Br
ie
se
n 
et
 a
l64
K
en
ya
 a
nd
  
C
on
go
A
nt
ib
io
tic
 e
ye
  
dr
op
s
33
N
R
N
R
H
PL
C
N
R
19
/3
3 
(5
8%
) 
 
su
bs
ta
nd
ar
d
Lo
w
 a
nd
 h
ig
h 
A
PI
%
N
og
ue
ir
a 
 
et
 a
l65
Br
az
il
A
nt
im
al
ar
ia
l  
m
ed
ic
in
es
9
N
R
Si
m
pl
e 
pa
ck
ag
e 
 
an
al
ys
is
H
PL
C
-U
v
D
is
so
lu
tio
n,
  
di
si
nt
eg
ra
tio
n,
  
ha
rd
ne
ss
, u
ni
fo
rm
ity
  
of
 w
ei
gh
t, 
an
d 
 
fr
ia
bi
lit
y 
te
st
s
4/
9 
(4
4%
) 
 
su
bs
ta
nd
ar
d
Fa
ili
ng
 o
nl
y 
vi
su
al
 in
sp
ec
tio
n 
an
d 
un
ifo
rm
ity
 o
f w
ei
gh
t
el
-D
ua
h 
 
an
d 
O
fo
ri
- 
K
w
ak
ye
66
G
ha
na
A
nt
im
al
ar
ia
l  
ar
te
m
is
in
in
- 
 
m
ed
ic
in
es
14
N
R
Fo
r 
ill
eg
al
 p
ri
nt
  
er
ro
rs
C
ol
or
im
et
ry
  
an
d 
T
LC
U
ni
fo
rm
ity
 o
f m
as
s,
  
cr
us
hi
ng
 s
tr
en
gt
h,
  
an
d 
di
si
nt
eg
ra
tio
n
13
/1
4 
(9
3%
) 
 
su
bs
ta
nd
ar
d
Lo
w
 o
r 
hi
gh
 A
PI
%
 a
nd
 fa
ili
ng
 
ph
ys
ic
al
 t
es
ts
K
ar
la
ge
 e
t 
al
67
M
ex
ic
o
A
nt
ib
io
tic
s,
  
w
ar
fa
ri
n,
  
le
vo
th
yr
ox
in
e 
 
an
d 
si
ld
en
afi
l
17
N
R
N
R
H
PL
C
w
ei
gh
t 
 
m
ea
su
re
m
en
t
5/
17
 (
30
%
) 
 
su
bs
ta
nd
ar
d
Lo
w
 A
PI
%
Pr
ib
lu
da
 e
t 
al
68
Se
ve
n 
 
co
un
tr
ie
s 
in
  
So
ut
h 
A
m
er
ic
a
A
nt
im
al
ar
ia
l
1,
66
3
N
R
Pa
ck
ag
e 
an
d 
la
be
l
T
LC
D
is
in
te
gr
at
io
n
19
3/
1,
66
3 
(1
1%
) 
 
su
bs
ta
nd
ar
d
ex
pi
re
d 
m
ed
ic
in
es
 m
os
tly
, l
ow
 
A
PI
%
, a
nd
 fa
ilu
re
 o
f d
is
in
te
gr
at
io
n 
te
st
s
K
le
in
 e
t 
al
69
G
ha
na
A
nt
im
al
ar
ia
l
33
N
R
Pa
ck
ag
e 
in
sp
ec
tio
n
N
M
R
N
R
1/
33
 (
3%
) 
 
su
bs
ta
nd
ar
d
Lo
w
 A
PI
%
eh
ia
ne
ta
 e
t 
al
70
N
ig
er
ia
A
nt
im
al
ar
ia
l  
ar
te
su
na
te
 a
nd
  
am
od
ia
qu
in
e 
 
co
m
bi
na
tio
n
13
N
R
Pa
ck
ag
e 
in
sp
ec
tio
n 
 
of
 e
xp
ir
y 
da
te
  
an
d 
re
gi
st
ra
tio
n
H
PL
C
N
R
11
/1
3 
(8
5%
) 
 
su
bs
ta
nd
ar
d
Lo
w
 a
nd
 h
ig
h 
A
PI
%
Integrated Pharmacy Research and Practice 2014:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
81
Counterfeit and substandard medicines in field quality surveys
Ba
te
 e
t 
al
71
17
 c
ou
nt
ri
es
  
fr
om
 a
ll 
 
co
nt
in
en
ts
A
nt
im
al
ar
ia
l, 
 
an
tib
io
tic
s,
 a
nd
  
an
tit
ub
er
cu
lo
si
s
89
9
N
R
Pa
ck
ag
e 
in
sp
ec
tio
n
T
LC
 a
nd
  
R
am
an
D
is
in
te
gr
at
io
n
15
%
 s
ub
st
an
da
rd
Fa
ilu
re
 o
f v
is
ua
l i
ns
pe
ct
io
n,
 lo
w
 
A
PI
%
, a
nd
 d
is
so
lu
tio
n 
fa
ilu
re
Se
ea
r 
et
 a
l72
In
di
a
C
ip
ro
flo
xa
ci
n,
  
ar
te
su
na
te
,  
an
d 
ri
fa
m
pi
ci
n
30
0
N
R
N
R
H
PL
C
-M
S
N
R
43
%
 s
ub
st
an
da
rd
Lo
w
 a
nd
 h
ig
h 
A
PI
%
A
kp
ab
io
 e
t 
al
73
N
ig
er
ia
A
nt
ib
io
tic
  
ci
pr
ofl
ox
ac
in
4
N
R
N
R
T
itr
at
io
n
U
ni
fo
rm
ity
 o
f  
w
ei
gh
t, 
ha
rd
ne
ss
,  
di
si
nt
eg
ra
tio
n,
 
di
ss
ol
ut
io
n,
  
an
d 
fr
ia
bi
lit
y
1/
4 
(2
5%
) 
 
su
bs
ta
nd
ar
d
Lo
w
 A
PI
%
, f
ai
lu
re
 o
f f
ri
ab
ili
ty
, a
nd
 
di
ss
ol
ut
io
n 
te
st
s
H
ad
i e
t 
al
74
In
do
ne
si
a
Fi
ve
 d
iff
er
en
t 
 
an
tib
io
tic
s
10
4
N
R
Pa
ck
ag
e 
in
sp
ec
tio
n
H
PL
C
N
R
18
%
 s
ub
st
an
da
rd
Lo
w
 A
PI
%
Ba
te
 a
nd
  
H
es
s7
5
G
ha
na
 a
nd
  
N
ig
er
ia
A
nt
im
al
ar
ia
l
33
9
N
R
Pa
ck
ag
e 
in
sp
ec
tio
n
T
LC
 a
nd
  
R
am
an
D
is
in
te
gr
at
io
n
23
%
 s
ub
st
an
da
rd
Fa
ilu
re
 o
f v
is
ua
l i
ns
pe
ct
io
n,
 lo
w
 
A
PI
%
, a
nd
 d
is
so
lu
tio
n 
fa
ilu
re
Le
sl
ie
 e
t 
al
76
Pa
ki
st
an
A
nt
im
al
ar
ia
l
9
N
R
N
R
H
PL
C
D
is
so
lu
tio
n
10
0%
 s
ub
st
an
da
rd
H
ig
h 
A
PI
%
 a
nd
 d
is
so
lu
tio
n 
fa
ilu
re
T
w
ag
ir
um
uk
iz
a 
 
et
 a
l77
R
w
an
da
A
nt
ih
yp
er
te
ns
iv
e 
 
dr
ug
s
10
N
R
N
R
H
PL
C
D
is
so
lu
tio
n
2/
10
 (
20
%
) 
 
su
bs
ta
nd
ar
d
Lo
w
 a
nd
 h
ig
h 
A
PI
%
A
li7
8
Pa
ki
st
an
A
nt
ib
io
tic
  
ce
ftr
ia
xo
ne
  
in
je
ct
io
n
96
N
R
N
R
H
PL
C
N
R
15
/9
6 
(1
6%
) 
 
su
bs
ta
nd
ar
d
Lo
w
 a
nd
 h
ig
h 
A
PI
%
Ba
te
 e
t 
al
79
G
ha
na
,  
In
di
a,
 K
en
ya
,  
N
ig
er
ia
,  
T
an
za
ni
a,
  
an
d 
U
ga
nd
a
A
nt
im
al
ar
ia
l, 
 
an
tib
io
tic
, a
nd
  
an
tim
yc
ob
ac
te
ri
al
78
N
R
N
R
T
LC
, n
ea
r-
 
in
fr
ar
ed
  
sp
ec
tr
os
co
py
,  
an
d 
R
am
an
D
is
in
te
gr
at
io
n
40
/7
8 
(5
1%
) 
 
su
bs
ta
nd
ar
d
Lo
w
 A
PI
%
 a
nd
 d
is
in
te
gr
at
io
n 
fa
ilu
re
Fo
tio
u 
et
 a
l80
T
ha
ila
nd
ep
oe
tin
  
al
fa
-p
re
fil
le
d 
 
sy
ri
ng
es
13
9
C
he
ck
ed
 b
at
ch
  
nu
m
be
rs
 w
ith
  
m
an
uf
ac
tu
re
r
Pr
im
ar
y 
an
d 
 
se
co
nd
ar
y 
pa
ck
ag
e 
 
an
d 
se
cu
ri
ty
  
fe
at
ur
es
H
PL
C
,  
el
ec
tr
op
ho
re
si
s 
 
an
d 
w
es
te
rn
  
bl
ot
tin
g
N
R
32
/1
39
 (
23
%
) 
 
su
bs
ta
nd
ar
d 
 
an
d 
di
ve
rt
ed
Ex
ce
ed
ed
 s
pe
ci
fic
 c
on
te
nt
 
re
qu
ir
em
en
t 
fo
r 
th
e 
pr
od
uc
t, 
an
d 
ba
tc
h 
nu
m
be
r 
m
at
ch
es
 
pr
od
uc
ts
 s
ol
d 
ou
ts
id
e 
th
e 
co
un
tr
y 
ac
co
rd
in
g 
to
 t
he
 m
an
uf
ac
tu
re
r
K
au
r 
et
 a
l81
T
an
za
ni
a
A
nt
im
al
ar
ia
l
30
4
N
R
N
R
H
PL
C
D
is
so
lu
tio
n
12
.5
%
  
su
bs
ta
nd
ar
d
Lo
w
 A
PI
%
 a
nd
 d
is
so
lu
tio
n 
fa
ilu
re
K
yr
ia
co
s 
et
 a
l82
Le
ba
no
n,
  
Sy
ri
a,
 Jo
rd
an
,  
eg
yp
t, 
an
d 
 
Sa
ud
i A
ra
bi
a
A
m
ox
ic
ill
in
  
an
tib
io
tic
  
in
 d
iff
er
en
t 
 
fo
rm
ul
at
io
ns
11
1
N
R
N
R
H
PL
C
N
R
56
%
 o
f c
ap
su
le
s 
 
su
bs
ta
nd
ar
d;
  
8%
 o
f s
us
pe
ns
io
ns
  
su
bs
ta
nd
ar
d
Lo
w
 A
PI
%
M
eo
s 
et
 a
l83
es
to
ni
a 
 
an
d 
R
us
si
a
A
nt
ib
io
tic
  
do
xy
cy
cl
in
e
8
N
R
Ba
si
c 
pa
ck
ag
e 
 
in
sp
ec
tio
n
H
PL
C
D
is
so
lu
tio
n
2/
8 
(2
5%
) 
 
su
bs
ta
nd
ar
d
Lo
w
 A
PI
%
 a
nd
 d
is
so
lu
tio
n 
fa
ilu
re
Br
on
ni
ko
va
  
et
 a
l84
es
to
ni
a 
 
an
d 
R
us
si
a
A
nt
ib
io
tic
  
am
ox
ic
ill
in
6
N
R
Ba
si
c 
pa
ck
ag
e 
 
in
sp
ec
tio
n
H
PL
C
 a
nd
 U
v
D
is
so
lu
tio
n
1/
6 
(1
6%
) 
 
su
bs
ta
nd
ar
d
D
is
so
lu
tio
n 
fa
ilu
re
v
ija
yk
ad
ga
  
et
 a
l85
T
ha
ila
nd
A
nt
im
al
ar
ia
l
36
9
N
R
Pa
ck
ag
e 
an
d 
la
be
l
T
LC
 a
nd
 H
PL
C
D
is
in
te
gr
at
io
n
23
/3
69
 (
6%
) 
su
bs
ta
nd
ar
d
Lo
w
 A
PI
%
 a
nd
 d
is
in
te
gr
at
io
n 
te
st
 
fa
ilu
re
(C
on
tin
ue
d)
Integrated Pharmacy Research and Practice 2014:3submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
82
Alghannam et al
T
ab
le
 4
 (
Co
nt
in
ue
d)
R
ef
er
en
ce
C
ou
nt
ry
M
ed
ic
in
e
Sa
m
pl
e 
 
si
ze
A
ut
he
nt
ic
at
e 
 
so
ur
ce
V
is
ua
l a
na
ly
si
s
C
he
m
ic
al
  
an
al
ys
is
P
hy
si
ca
l a
na
ly
si
s
R
es
ul
ts
T
yp
e 
of
 s
ub
st
an
da
rd
/s
pu
ri
ou
s/
fa
ls
el
y 
la
b
el
ed
/f
al
si
fi
ed
/
co
un
te
rf
ei
t 
m
ed
ic
in
e 
pr
ob
le
m
Lo
n 
et
 a
l86
C
am
bo
di
a
A
nt
im
al
ar
ia
l
45
1
O
ne
 c
om
pa
ny
  
w
as
 in
ve
st
ig
at
ed
  
by
 c
on
ta
ct
  
w
ith
 lo
ca
l  
au
th
or
iti
es
v
is
ua
l i
ns
pe
ct
io
n 
 
M
in
ila
b®
T
LC
D
is
in
te
gr
at
io
n
12
2/
45
1 
(2
7%
) 
 
su
bs
ta
nd
ar
d
Lo
w
 A
PI
%
 a
nd
 d
is
in
te
gr
at
io
n 
te
st
 
fa
ilu
re
; o
ne
 il
le
ga
l m
an
uf
ac
tu
re
r 
id
en
tifi
ed
A
m
in
 e
t 
al
2
K
en
ya
A
nt
im
al
ar
ia
l
11
6
N
R
Pa
ck
ag
e 
an
d 
 
st
or
ag
e 
ar
ea
  
in
sp
ec
tio
n
U
v
 a
nd
 H
PL
C
D
is
so
lu
tio
n
47
/1
16
 (
40
%
) 
 
su
bs
ta
nd
ar
d
Lo
w
 A
PI
%
 a
nd
 d
is
so
lu
tio
n 
fa
ilu
re
A
bd
o-
R
ab
bo
  
et
 a
l87
Y
em
en
A
nt
im
al
ar
ia
l  
ta
bl
et
 a
nd
 s
yr
up
50
N
R
N
R
U
v
 a
nd
 H
PL
C
D
is
so
lu
tio
n
16
/5
0 
(3
2%
) 
 
su
bs
ta
nd
ar
d
Lo
w
 A
PI
%
, h
ig
h 
A
PI
%
 a
nd
 
di
ss
ol
ut
io
n 
fa
ilu
re
R
oo
kk
ap
an
  
et
 a
l88
T
ha
ila
nd
A
nt
itu
be
rc
ul
os
is
52
O
ne
 q
ua
lit
y 
 
re
po
rt
 w
as
  
re
qu
es
te
d 
 
fr
om
 a
  
m
an
uf
ac
tu
re
r
T
ab
le
t 
in
sp
ec
tio
n
U
v
 a
nd
 H
PL
C
D
is
so
lu
tio
n
37
%
 s
ub
st
an
da
rd
Fa
ilu
re
 o
f v
is
ua
l i
ns
pe
ct
io
n,
 lo
w
 
A
PI
%
, a
nd
 d
is
so
lu
tio
n 
fa
ilu
re
K
ay
um
ba
  
et
 a
l89
R
w
an
da
 a
nd
  
T
an
za
ni
a
A
nt
im
ic
ro
bi
al
  
an
d 
an
tim
al
ar
ia
l  
dr
ug
s
33
N
R
N
R
H
PL
C
D
is
so
lu
tio
n
4/
33
 (
12
%
) 
 
su
bs
ta
nd
ar
d
D
is
so
lu
tio
n 
fa
ilu
re
M
in
zi
 e
t 
al
90
T
an
za
ni
a
A
nt
im
al
ar
ia
l
33
N
R
Ba
si
c 
pa
ck
ag
e 
 
in
fo
rm
at
io
n
T
LC
, H
PL
C
D
is
so
lu
tio
n
12
/3
3 
(3
6%
) 
 
su
bs
ta
nd
ar
d
Lo
w
 A
PI
%
 a
nd
 d
is
so
lu
tio
n 
fa
ilu
re
O
bo
do
zi
e 
 
et
 a
l91
N
ig
er
ia
A
nt
ib
io
tic
  
in
 d
iff
er
en
t 
 
fo
rm
ul
at
io
n
22
N
R
N
R
H
PL
C
N
R
9/
22
 (
41
%
) 
su
bs
ta
nd
ar
d
Lo
w
 a
nd
 h
ig
h 
A
PI
%
La
se
rs
on
  
et
 a
l92
Se
ve
n 
 
di
ffe
re
nt
  
co
un
tr
ie
s
A
nt
i-T
B
71
N
R
Ba
si
c 
pa
ck
ag
e 
 
in
fo
rm
at
io
n
T
LC
 a
nd
  
LC
-M
S
N
R
10
%
 s
ub
st
an
da
rd
Lo
w
 A
PI
%
K
en
yo
n 
et
 a
l93
Bo
ts
w
an
a
A
nt
itu
be
rc
ul
os
is
  
fix
ed
-d
os
e 
 
co
m
bi
na
tio
n
13
N
R
N
R
T
LC
, L
C
,  
an
d 
U
v
N
R
4/
13
 (
31
%
) 
 
su
bs
ta
nd
ar
d
Lo
w
 a
nd
 h
ig
h 
A
PI
%
A
bb
re
vi
at
io
ns
: A
PI
, a
ct
iv
e 
ph
ar
m
ac
eu
tic
al
 in
gr
ed
ie
nt
; N
R
, n
ot
 r
ep
or
te
d;
 H
PL
C
, h
ig
h-
pe
rf
or
m
an
ce
 li
qu
id
 c
hr
om
at
og
ra
ph
y;
 T
LC
, t
hi
n-
la
ye
r 
ch
ro
m
at
og
ra
ph
y;
 N
IR
, n
ea
r-
in
fr
ar
ed
 s
pe
ct
ro
sc
op
y;
 U
V
, u
ltr
av
io
le
t 
sp
ec
tr
os
co
py
; L
C
-M
S,
 li
qu
id
 
ch
ro
m
at
og
ra
ph
y-
m
as
s 
sp
ec
tr
om
et
ry
; N
M
R
, n
uc
le
ar
 m
ag
ne
tic
 r
es
on
an
ce
 s
pe
ct
ro
sc
op
y;
 IR
, i
nf
ra
re
d 
sp
ec
tr
os
co
py
; T
B,
 t
ub
er
cu
lo
si
s.
Integrated Pharmacy Research and Practice 2014:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
83
Counterfeit and substandard medicines in field quality surveys
medicines such as warfarin and levothyroxine.67 Two  studies 
from Eastern Europe found some problems regarding low 
API% and dissolution failures when a limited number of 
antibiotics were analyzed in Estonia and Russia.83,84 No 
studies could be identified that addressed medicine quality 
problems in the Australian continent.
Neglected noncommunicable  
medicines in SSFFC surveys
Most of the studies in this review were found to explore 
medicines used to treat infectious diseases such as malaria 
and tuberculosis. Medicines used to treat noninfectious 
diseases, also known as noncommunicable disease (NCD) 
medicines or chronic disease medicines, were only found 
in a few studies that presented some medicine quality 
problems.31,32,47,58–60,67,77,80 However, on a global scale, 
NCDs and their medicines must not be ignored. The WHO 
estimates that NCDs kill more than 36 million people each 
year, of which 29 million deaths (80%) occur in low- and 
middle-income countries.97 The currently available literature 
on medicine quality does not reflect the wider use of NCDs 
and their medicines globally, including in lower-income 
countries. This issue needs to be addressed rapidly, as 
recent evidence from Pakistan reported the death of more 
than 100 people after the administration of the antianginal 
medicine isosorbide mononitrate contaminated with large 
amounts of pyrimethamine.98,99 Elsewhere, the US Food and 
Drug Administration recently issued warnings regarding 
counterfeit cancer medicines.100,101 Furthermore, evidence of 
counterfeiting involving NCD medicines such as diabetes 
treatments were found in illicit or lifestyle drugs, which may 
have significant implications for the public health and could 
result in death.17,102,103 Therefore, it is recommended that we 
extend the attention of future medicine quality surveys glob-
ally beyond infectious diseases medicines and on to NCD 
medicines (and widely available treatments of diabetes and 
cardiovascular diseases in particular), in addition to cancer 
treatments and narrow therapeutics index medicines, as 
they could have severe health implications for the affected 
population.
Type of analysis used in SSFFC surveys
All studies included in this review performed chemical 
analysis for the identification and/or quantification of the 
API available in selected samples, in accordance with our 
methodological approach. High-performance liquid chroma-
tography and TLC were the most widely used chemical ana-
lytical techniques available in the selected articles,  possibly 
because of their wide acceptance in the academic field and 
their application in many pharmacopeial references. It is 
suggested that this would be a logical and possibly important 
consideration for future scholars interested in conducting 
medicine quality surveys to ensure the acceptance of their 
findings within the academic field.
Physical analysis tests were performed to complement 
chemical analysis in approximately two-thirds of the selected 
studies, particularly disintegration and dissolution tests for 
solid dosage forms. This can be attributed to the availability 
of specific physical tests in different pharmacopoeias in addi-
tion to the use of physical information about the medicinal 
product to predict the bioavailability of medicines.2,45,88 
However, such physical analysis tests could only be used as 
a bioavailability indicator and cannot substitute lengthy and 
expensive bioavailability studies.89,93 Moreover, it is important 
to note that performing physical analysis only on medicinal 
samples can be considered inadequate if the objective of the 
study was to determine medicine quality issues, as it cannot 
be determined whether the correct API and its quantity are 
present in medicine samples, as specified in the WHO defini-
tion of substandard and counterfeit medicines.3–5
Package inspection is another popular type of medicine 
analysis that was also found in nearly two-thirds of the medi-
cine quality surveys in this review. On the basis of primary 
and secondary package information, the majority of reports 
seek obvious spelling errors, suspicious holograms compared 
with known genuine samples, and basic label misinforma-
tion such as medicine name, dosage, manufacturer details, 
expiry date, and lot number (Tables 1, 2, and 4). The WHO 
definition of counterfeit medicines highlights packaging 
information significance and could have influenced the wide 
use of package information among medicine quality surveys.3 
Furthermore, packaging information of medicines has been 
a valuable mode of analysis in the relevant literature and 
has revealed many counterfeit medicines that have passed 
chemical identification tests.34,41,43 A tool kit developed by 
the World Health Professions Alliance and the International 
Pharmaceutical Federation for visual inspection of medicines 
can be used for a systematic package inspection by health 
care professionals and scholars both in practice and in future 
investigative projects.104
A less common level of analysis available in the litera-
ture is the authentication of medicine source via contact 
with the medicine manufacturer and local or international 
health authorities. We have identified only ten research 
articles that attempted to authenticate the source of the 
medicine samples.12,33,35,40,46,56,62,80,86,88 Perhaps researchers 
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may not  guarantee adequate responses to their queries 
from other parties, as some have suggested.33,35 It could 
also be possible that authenticating the source may not be 
within the scope of a particular medicine quality survey, 
as it could be only focused on substandard medicines 
issue.51  Nevertheless, the WHO definition of counterfeit 
medicines clearly describes the deliberate and fraudulent 
misrepresentation of the medicine source as a characteris-
tic of a counterfeit  medicine.3 Moreover, according to the 
Pharmaceutical Security Institute, counterfeit medicines 
are currently increasing in terms of reported incidences 
worldwide and can no longer be ignored.105 We recognize 
that obtaining authentication confirmation of medicine 
sources could be difficult in studies collecting samples from 
street markets; however, this task could be less complex 
when samples are collected from pharmacies or hospitals, 
as official records and documentation of medicines are 
expected to exist. Furthermore, according to the limited 
studies that reported authentication analysis in this review, 
many counterfeit cases were found by confirmation from 
manufacturers or health authorities of a nonauthentic batch 
of medicines, even if samples contained the correct API 
when chemically analyzed.35,46,86
Overall, there were very few research articles that per-
formed all four levels of analysis: chemical, physical, package 
inspection, and authentication of source.33,35,40,62,86,88 Future 
medicine quality surveys are advised to consider performing 
all four types of analysis for a more holistic approach, and 
equally, to address the possibility of finding either counterfeit 
or substandard medicines during an investigation. Further, it 
was noted that none of the medicine quality surveys examined 
patient information leaflets within medicinal packages to 
check for accuracy and up-to-date information made avail-
able to patients. Some studies, particularly in the Middle 
East, have found disagreement between patient information 
leaflets in some medicine samples when compared with 
national formularies.106,107 Therefore, the addition of patient 
information leaflets to examination of medicine samples in 
medicine quality survey studies is open for debate among 
the scientific community.
Prevalence of SSFFC
Our data suggest that reports of substandard medicines are 
more widely available in the literature, particularly medicines 
with incorrect API% and failure of dissolution/disintegration 
tests, than counterfeit medicine reports (Tables 1–4). These 
findings are in line with previous reports that suggested that 
substandard medicines are more prevalent than counterfeits 
and require more global attention.23,24 This phenomenon 
might be attributed to poor manufacturing practices or 
extreme weather conditions in some countries, accompanied 
by inadequate storage conditions.4,5,82 However, because 
the majority of cited articles in this review did not conduct 
authentication processes via contact with manufacturers 
and/or health authorities, as previously mentioned, medicine 
counterfeiting remains a possibility that has not been largely 
explored. Hence, considering the available data, it cannot be 
determined whether substandard medicines are indeed more 
prevalent than counterfeit medicines at this time. Future 
medicine quality researchers are therefore encouraged to 
remain vigilant about counterfeiting possibility and conduct 
all types of analysis including chemical, physical, package 
inspection, and authentication efforts to determine the type 
of medicine quality problem more accurately.
Limitations of this review
This systematic review is not without limitations. Articles 
conducting chemical analysis were a prerequisite for inclu-
sion in this review. We focused only on prospective field 
quality surveys and excluded reporting of any studies with 
retrospective or previously seized SSFFC medicines in the 
literature. Studies proposing novel chemical or physical ana-
lytical techniques and methods are typically conducted on 
previously seized samples of SSFFC medicines, and there-
fore would not be covered within this review. Our search 
strategy has limited our findings to the search terms used 
and the databases searched. We did not search for articles 
on the Internet in an attempt to preserve the systematic 
nature of our study. The Internet source of medicines was 
beyond the scope of our review. Relevant articles from the 
bibliographical list of available studies were only included 
on some occasions and cannot be considered exhaustive. 
The included articles were not assessed for the quality of 
their methodology, which was found to vary considerably 
among the selected articles. The primary author was the 
only individual who performed the identification, selection, 
and inclusion of articles in this review. No attempt was 
made to calculate prevalence rates of SSFFC medicines or 
test for statistical significance, as it would have resulted 
in the exclusion of most articles from this review, as most 
reported studies used convenience sampling and/or with 
limited sample size.11
Strengths of this review
This review has several strengths. To our knowledge, it 
is only the second systematic review on the subject of 
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SSFFC  medicines. Evidence of SSFFC medicines in terms of 
nature and type of analysis were discussed. This information 
would most likely aid government agencies and health care 
authorities and scientists interested in the medicine quality 
issues in developing or improving current policies and prac-
tices. It was the intention of this review to help interested 
parties identify and describe SSFFC medicine problems with 
up-to-date scientific evidence. Further, this review high-
lighted neglected medicine types and neglected geographical 
location in terms of scientific research addressing SSFFC 
medicines. This could invite more research projects address-
ing these neglected medicines and geographical locations to 
improve current knowledge on the issue and maintain patient 
safety. Moreover, this review has identified the limited sci-
entific research, conducting field quality surveys on SSFFC 
medicines, using all four levels of analysis, in an attempt to 
encourage future researchers to explore all possibilities when 
conducting a medicine quality survey in any settings.
Conclusion
The problem of SSFFC medicines is evident worldwide. 
Potential harm to patients’ health requires global collabora-
tion exceeding the status quo. Limited research addressing 
SSFFCC medicines was noted in several parts of the world, 
including the Middle East, North Africa, and Australia. Simi-
larly, more research is required to address SSFFC medicines 
from noncommunicable medicine classes, including narrow 
therapeutic index and chronic medicines, as current scien-
tific knowledge regarding these medicines remains limited 
despite their popularity and media reports of the existence 
of SSFFC medicine problems in such therapeutic classes. 
Furthermore, the current focus of published research on 
chemical and physical analysis of medicine samples could 
overlook the possibility of counterfeiting if additional steps 
of analysis were performed, including package inspection 
and authentication of source via contact with manufacturers 
and health authorities. Future medicine quality surveys are 
encouraged to perform all four levels of analysis to explore 
all possibilities of substandard and counterfeit medicines that 
may be present in their selected sample of medicines. Such 
an approach would be beneficial in determining the type and 
prevalence rate of medicine quality problems in any setting 
and could consequently determine the most appropriate 
strategies to combat their threats.
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